The Parker Institute for Cancer Immunotherapy and the Cancer Research Institute (CRI) are moving forward on an immuno-oncology clinical research collaboration study.
According to a press release from the Parker Institute, scientists and researchers will work together using an ecosystem of advanced translational tools, precision immunotherapy and cutting-edge bioanalytical expertise to ensure that highly reliable data can be gathered and used effectively in the future.
“Bristol-Myers Squibb is initiating this unique collaboration with a goal of accelerating the identification and development of new treatment options for patients who are facing very serious disease,” said Dr. Fouad Namouni, head of Oncology Development, Bristol-Myers Squibb. “We are excited to partner with the Parker Institute and the Cancer Research Institute to leverage the unique translational capabilities of their networks and explore novel mechanisms of action in the field of I-O.”
“One of our goals is to help facilitate collaborations between academia and industry to help advance cancer research,” said Jeffrey Bluestone, CEO and president of the Parker Institute for Cancer Immunotherapy. “Partnering with Bristol-Myers Squibb, a renowned leader in the field of immuno-oncology development, is a major leap forward for us. We could not be more enthusiastic to start this collaboration, which we believe will accelerate the process of turning important lab discoveries by our investigators into the potential for much needed treatments for patients.”
To tap the full potential of cutting-edge cancer immunotherapy techniques, coordination and logistical support among high-tech innovators such as CRI and the Parker Institute is essential, according to Jill O’Donnell-Tormey, CEO and director of scientific affairs at CRI.
“Collaboration with industry leaders like Bristol-Myers Squibb will be essential to hastening the development of new cancer immunotherapies,” said O’Donnell-Tormey.
